Myo-Inositol, With or Without Selenium, in Hashimoto's Thyroiditis and Autoimmune Thyroid Disease: A Scoping Review
Abstract
Hernando Vargas-Uricoechea, Julia Devoz-Munoz and Alejandro Castellanos-Pinedo
Background: Hashimoto's thyroiditis (HT) is the leading autoimmune cause of hypothyroidism in iodine-sufficient regions. Selenium supplementation is an established adjunct in HT, and myo-inositol has more recently been investigated, alone or combined with selenium, as a modulator of thyroid-stimulating hormone (TSH) signaling and autoimmunity.
Objective: To systematically map the extent, nature, and distribution of the available evidence on myo-inositol supplementation — alone or combined with selenium — across the spectrum of autoimmune thyroid disease.
Methods: A multi-database search (PubMed, Web of Science, Scopus, ScienceDirect, SpringerLink, Google Scholar) was supplemented by citation searching of related compehensive reviews identified during screening. Sources reporting original data on myo-inositol supplementation (alone, combined with selenium, or compared against selenium or other micronutrients) in adults with HT or autoimmune thyroiditis across any thyroid-function status were eligible, regardless of study design.
Results: The charted evidence spans thyroid function and autoantibody titers in SCH, thyroid structural change on ultrasound, prevention of progression to overt hypothyroidism in euthyroid autoimmune thyroiditis, subjective wellbeing and quality of life, sexual function and depressive symptoms under different micronutrient monotherapies, and a novel comorbid population with migraine. Only three studies directly compared combined myo-inositol plus selenium against selenium monotherapy.
Conclusions: The evidence base on myo-inositol in autoimmune thyroid disease is small, heterogeneous in design and population. Its principal gaps lie outside that narrow question: longer-term progression data, patient-reported outcomes, head-to-head comparisons against other micronutrients, and evidence in comorbid populations. These gaps, rather than a further pooled TSH estimate, define the priorities for future primary research.

